Case Studies

  1. Human Genome Sciences: Aegis Discoverant for Emerging Biotechnology Companies

    Human Genome Sciences (HGS) is committed to solving critical medical challenges through careful planning, relentless resilience, the best scientific minds, and rigorous clinical trials. For the company, success comes by design – and by working systematically to achieve breakthrough results one careful step at a time. HGS’ manufacturing and process development capability represents a significant strategic advantage. The company is able to produce and purify multiple protein and antibody drugs in two state-of-the-art process development and manufacturing facilities – totaling approximately 400,000 square feet and offering both small-scale and large-scale production.

  2. Merck Serono Discovers the Value of Process Improvement

    Gartner analyst, Wayne McDonnell, spoke with Merck Serono’s EVP of Operations, Dr. Hanns-Eberhard Erle, and their Scientific Director of New Technologies, Dr. Gianni Baer, about Merck Serono’s experience using Discoverant, Aegis Analytical’s Enterprise Manufacturing Intelligence software.

  3. Improving Process Predictablity Across Multiple Plants

    A multinational Pharmaceutical company was trying to gain control over process predictability for two of their blockbuster products.

  4. Streamline Annual Product Reviews

    An international company with a broad line of products in Consumer Packaged Goods, Pharmaceutical and Biotechnology wanted to improve their ability to access and analyze manufacturing process data on-demand in order to improve efficiency.

  5. Improve Process Understanding, Stability and Product Quality

    A large Biotech company was experiencing production issues with two flagship products, and struggling to identify the root causes. They wanted to improve their process understanding to identify the critical process parameters.

  6. Reduce Process Variability

    A leading Pharmaceutical company was struggling with process variability in a complex step in their manufacturing process. This variability led regulatory inspectors to question the company's specification limits and their ability to manufacture the product reliably. The product generated over $3B of revenue annually so it was critical to find a solution.